Joshua S Friedman, Benjamin H Durham, Anne S Reiner, Mariko Yabe, Kseniya Petrova-Drus, Ahmet Dogan, Melissa Pulitzer, Klaus J Busam, Jasmine H Francis, Raajit K Rampal, Gary A Ulaner, Ryan Reddy, Randy Yeh, Vaios Hatzoglou, Mario E Lacouture, Veronica Rotemberg, Roei D Mazor, Oshrat Hershkovitz-Rokah, Ofer Shpilberg, Gaurav Goyal, Ronald S Go, Jithma P Abeykoon, Karen Rech, Diana Morlote, Shiraz Fidai, Vedavyas Gannamani, Maryam Zia, Omar Abdel-Wahab, Katherine S Panageas, Marc K Rosenblum, Eli L Diamond
Histiocytic neoplasms are diverse clonal haematopoietic disorders, and clinical disease is mediated by tumorous infiltration as well as uncontrolled systemic inflammation. Individual subtypes include Langerhans cell histiocytosis (LCH), Rosai-Dorfman-Destombes disease (RDD) and Erdheim-Chester disease (ECD), and these have been characterized with respect to clinical phenotypes, driver mutations and treatment paradigms. Less is known about patients with mixed histiocytic neoplasms (MXH), that is two or more coexisting disorders...
April 12, 2024: British Journal of Haematology